Results 71 to 80 of about 102,788 (290)

Characterizing and prognosticating chronic lymphocytic leukemia in the elderly: prospective evaluation on 455 patients treated in the United States. [PDF]

, 2017
BACKGROUND: Median age at diagnosis of patients with chronic lymphocytic leukemia (CLL) is \u3e 70 years. However, the majority of clinical trials do not reflect the demographics of CLL patients treated in the community.
Bhushan, Shriya, Davids, Matthew S., Flick, E. Dawn, Flowers, Christopher R., Grinblatt, David L., Kiselev, Pavel, Lamanna, Nicole, Mato, Anthony, Nabhan, Chadi, Sharman, Jeff P., Sullivan, Kristen, Swern, Arlene S., Weiss, Mark A.   +12 more
core   +3 more sources

Multiple productive immunoglobulin heavy chain gene rearrangements in chronic lymphocytic leukemia are mostly derived from independent clones

Haematologica, 2014
In chronic lymphocytic leukemia, usually a monoclonal disease, multiple productive immunoglobulin heavy chain gene rearrangements are identified sporadically. Prognostication of such cases based on immunoglobulin heavy variable gene mutational status can
Karla Plevova, Hana Skuhrova Francova, Katerina Burckova, Yvona Brychtova, Michael Doubek, Sarka Pavlova, Jitka Malcikova, Jiri Mayer, Boris Tichy, Sarka Pospisilova   +9 more
doaj   +1 more source

Venetoclax inhibits autophagy in chronic lymphocytic leukemia cells

Autophagy Reports, 2023
Venetoclax (VCX) is a BCL2 inhibitor approved for treating B cell-derived leukemia, including chronic lymphocytic leukemia (CLL). VCX’s role in apoptosis induction is well-defined, whereas its other mechanistic roles need to be clarified. Autophagy is an
Yongqiang Chen, Sara E. F. Kost, Xiaoyan Yang, Versha Banerji, James B. Johnston, Sachin Katyal, Spencer B. Gibson   +6 more
doaj   +1 more source

Strategies to Design and Optimize Artificial Antigen‐Presenting Cells for T Cell Expansion in Cancer Immunotherapy

Advanced Functional Materials, EarlyView.
This review highlights recent advances in engineering artificial antigen‐presenting cells (aAPCs) as alternatives to dendritic cells for T cell expansion. Key design principles inspired by the immunological synapse are discussed, with emphasis on strategies for polyclonal and antigen‐specific T cell expansion.
Nguyen Thi Nguyen, Yu Seok Youn
wiley   +1 more source

Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. [PDF]

, 2017
Signaling via the B cell receptor (BCR) plays an important role in the pathogenesis and progression of chronic lymphocytic leukemia (CLL). This is underscored by the clinical effectiveness of ibrutinib, an inhibitor of Bruton's tyrosine kinase (BTK) that
Chen, L, Chen, Y, Choi, MY, Cui, B, Kipps, TJ, Rassenti, LZ, Widhopf Ii, GF, Wu, Christina, Yu, J, Zhang, L   +9 more
core  

Direct admission to the intensive care unit from the emergency department and mortality in critically ill hematology patients [PDF]

, 2019
Background: The aim of this study was to assess the benefit of direct ICU admission from the emergency department (ED) compared to admission from wards, in patients with hematological malignancies requiring critical care.
Azoulay, Elie, Benoit, Dominique, Bruneel, Fabrice, Chevret, Sylvie, Demoule, Alexandre, Kouatchet, Achille, Lebert, Christine, Lemiale, Virginie, Meert, Anne-Pascale, Mirouse, Adrien, Mokart, Djamel, Nyunga, Martine, Perez, Pierre, Peyrony, Olivier, Pène, Frédéric   +14 more
core   +2 more sources

Successful long-term monotherapy with rituximab in a patient with chronic lymphocytic leukemia of the B-cell-lineage: a case report

Journal of Medical Case Reports, 2008
Introduction Treatment of chronic lymphocytic leukemia of the B-cell-lineage is strongly based upon clinical staging because of the heterogeneous clinical course of this disease.
Sturm Isrid, Oertel Joachim, Oertel Stephan, Westermann Jörg, Pezzutto Antonio   +4 more
doaj   +1 more source

“Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia’’ [PDF]

Blood Cancer Journal, 2013
AbstractDespite significant progress in treatment, chronic lymphocytic leukemia (CLL) remains an incurable disease. Advances have been made to understand the molecular pathogenesis underlying CLL progression and treatment resistance. We here review the available evidences concerning the role of the B-cell receptor (BCR) and the tumor microenvironment ...
Pablo Oppezzo, Guillermo Dighiero, Guillermo Dighiero   +2 more
openaire   +3 more sources

Biological and technical complexities in analyzing extracellular vesicle immune interactions in B‐cell malignancies

FEBS Letters, EarlyView.
Daniel Bachurski, Michael Hallek
wiley   +1 more source

Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes

Advanced Functional Materials, EarlyView.
Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth, Neal I. Callaghan, Locke Davenport Huyer   +2 more
wiley   +1 more source